Edvinsson Lars, Krause Diana N
Division of Experimental Vascular Research, Department of Clinical Sciences, Lund University, Sölvegatan 19, 22100, Lund, Sweden.
Department of Experimental Research, Glostrup Research Institute, CopenhagenUniversity, Copenhagen, Denmark.
Transl Stroke Res. 2025 Jun;16(3):952-961. doi: 10.1007/s12975-024-01234-z. Epub 2024 Feb 9.
Patients who initially survive the rupture and repair of a brain aneurysm often take a devastating turn for the worse some days later and die or suffer permanent neurologic deficits. This catastrophic sequela is attributed to a delayed phase of global cerebral ischemia (DCI) following aneurysmal subarachnoid hemorrhage (aSAH), but we lack effective treatment. Here we present our view, based on 20 years of research, that the initial drop in blood flow at the time of rupture triggers genomic responses throughout the brain vasculature that manifest days later as increased vasoconstriction and decreased cerebral blood flow. We propose a novel treatment strategy to prevent DCI by early inhibition of the vascular mitogen-activated protein kinase (MAPK) pathway that triggers expression of vasoconstrictor and inflammatory mediators. We summarize evidence from experimental SAH models showing early treatment with MAPK inhibitors "switches off" these detrimental responses, maintains flow, and improves neurological outcome. This promising therapy is currently being evaluated in clinical trials.
最初在脑动脉瘤破裂和修复后存活下来的患者,往往会在几天后病情急剧恶化,最终死亡或留下永久性神经功能缺损。这种灾难性的后遗症归因于动脉瘤性蛛网膜下腔出血(aSAH)后的迟发性全脑缺血(DCI)阶段,但我们缺乏有效的治疗方法。在此,基于20年的研究,我们提出如下观点:破裂时最初的血流下降会触发全脑血管系统的基因组反应,这些反应在数天后表现为血管收缩增强和脑血流量减少。我们提出了一种新的治疗策略,即通过早期抑制触发血管收缩剂和炎症介质表达的血管丝裂原活化蛋白激酶(MAPK)途径来预防DCI。我们总结了来自实验性SAH模型的证据,这些证据表明,用MAPK抑制剂进行早期治疗可“关闭”这些有害反应,维持血流量,并改善神经功能结局。目前,这种有前景的疗法正在临床试验中进行评估。